Individuals diagnosed with cancer can undergo genome sequencing of the cancer specimen to obtain a molecular understanding of biological pathways that might be affected and possible options for treatment. The cancer sample alone can be analyzed, but sequences of both cancerous and normal tissues will provide a more accurate determination of mutations that are present only in the cancer sample. A blood sample is required for normal tissue sequencing. Additional diagnostic tools such as RNA transcriptomics (which measures expression of the genome in cancer cells) and proteomics (which measures the production of proteins from RNA transcripts), can be employed to resolve the molecular nature of the cancer. The molecular nature of the cancer can help indicate appropriate FDA-approved or developmental treatment options, and therapies to which the cancer may be resistant. If a treatment course is discovered that includes experimental medication, the client and his or her oncologist will be informed of relevant clinical trials. Tests are not a guarantee of successful outcome. The whole genome sequence will be analyzed for additional informative DNA variations that unrelated to cancer, and these results will be provided in a customizable Analysis Report along with a digital copy of the entire DNA sequence in the genome.